Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Cowen encouraged by Cerus data on Intercept in light of new coronavirus » 14:39
01/23/20
01/23
14:39
01/23/20
14:39
CERS

Cerus

$4.50 /

+0.19 (+4.41%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings noted that Cerus highlighted several publications that have shown the Intercept Blood System to be an effective mitigation tool for inactivating members of the coronavirus family similar to the 2019 novel coronavirus that has emerged. The analyst, who said he is encouraged by the data and continues to view Intercept as "the premier platform to help secure the safety of the global blood supply," keeps an Outperform rating on Cerus shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Inovio rises, Macau casino operators dip again as quarantine in China expands » 10:52
01/23/20
01/23
10:52
01/23/20
10:52
INO

Inovio

$3.67 /

+0.23 (+6.69%)

, LVS

Las Vegas Sands

$69.19 /

-0.23 (-0.33%)

, WYNN

Wynn Resorts

$139.52 /

-0.59 (-0.42%)

, MLCO

Melco Resorts & Entertainment

$21.79 /

-0.52 (-2.33%)

, TWST

Twist Bioscience

$22.61 /

-0.31 (-1.35%)

, CODX

Co-Diagnostics

$2.09 /

+0.97 (+86.61%)

, CERS

Cerus

$4.40 /

+0.09 (+2.09%)

Shares of Inovio (INO)…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cerus publishes study on inactivation of MERS coronavirus using Intercept » 08:37
01/23/20
01/23
08:37
01/23/20
08:37
CERS

Cerus

$4.31 /

-0.18 (-4.01%)

Cerus announced the…

Cerus announced the publication of a study in Transfusion Medicine on the inactivation of the Middle Eastern Respiratory Syndrome, or MERS, coronavirus in human platelet concentrates using the Intercept Blood System for platelets. This study follows prior publications on the inactivation of the MERS coronavirus in human plasma and the inactivation of the Severe Acute Respiratory Syndrome, or SARS, coronavirus in human platelets. A new coronavirus outbreak is currently ongoing in China, with the first imported U.S. case confirmed on Tuesday. The genetic sequence of the new coronavirus, 2019-nCoV, is at least 70% similar to SARS-CoV4. A coronavirus is a kind of common virus that causes an infection in the upper respiratory tracts. More serious coronaviruses, such as MERS and SARS, can cause severe respiratory illness. The Intercept Blood System is effective in reducing the risk of transfusion-transmitted infections across a broad spectrum of known and potentially emerging pathogens by cross-linking the pathogens' nucleic acids, and thereby blocking the replication of viruses, bacteria, and parasites present in the blood product. In contrast, with testing, emerging pathogens need to be identified and could take time for new tests to be developed and licensed.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Cerus signs five-year commercial contract with Swiss Transfusion SRC » 08:41
12/12/19
12/12
08:41
12/12/19
08:41
CERS

Cerus

$3.85 /

+0.01 (+0.26%)

Cerus announced that it…

Cerus announced that it has signed a new five-year commercial contract with Swiss Transfusion SRC, a company of the Swiss Red Cross, for purchase of the Intercept Blood System. The new agreement includes both Intercept platelet and plasma kits in addition to Illuminators and service contracts. The Cerus partnership with Swiss Transfusion SRC to develop a whole blood pathogen inactivation system is also continuing in an effort to find a solution to improve the safety of transfusion practice in Africa. The program is expected to begin clinical studies in the Cote d'Ivoire in 2020. In many parts of the world with limited resources, there is not enough blood to save women's lives with severe postpartum haemorrhage, to treat children with malaria infection-induced severe anaemia, or to reduce the burden of sickle cell disease and other haemoglobinopathies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Stifel to hold a conference » 04:55
11/20/19
11/20
04:55
11/20/19
04:55
CBAY

CymaBay

$5.49 /

+0.03 (+0.55%)

, ALXN

Alexion

$110.65 /

+2.71 (+2.51%)

, CBIO

Catalyst Biosciences

$5.18 /

-0.105 (-1.99%)

, QURE

uniQure

$54.98 /

+1.87 (+3.52%)

, GTHX

G1 Therapeutics

$22.72 /

+0.32 (+1.43%)

, HZNP

Horizon Therapeutics

$30.49 /

-0.23 (-0.75%)

, IONS

Ionis Pharmaceuticals

$58.04 /

+0.27 (+0.47%)

, SILK

Silk Road Medical

$36.28 /

-1.27 (-3.38%)

, SAGE

Sage Therapeutics

$147.89 /

+2.28 (+1.57%)

, KIN

Kindred Biosciences

$7.48 /

+0.14 (+1.91%)

, ACOR

Acorda Therapeutics

$1.58 /

-0.04 (-2.48%)

, MASI

Masimo

$153.27 /

+3.34 (+2.23%)

, IRIX

Iridex

$1.91 /

-0.12 (-5.91%)

, BSX

Boston Scientific

$42.63 /

+0.34 (+0.80%)

, PRVL

Prevail Therapeutics

$12.49 /

+1.45 (+13.13%)

, SUPN

Supernus

$21.76 /

-0.28 (-1.27%)

, EVLO

Evelo Biosciences

$5.64 /

-0.6 (-9.62%)

, HRC

Hill-Rom

$107.23 /

+2.64 (+2.52%)

, SVRA

Savara

$0.91 /

+0.0064 (+0.71%)

, AERI

Aerie Pharmaceuticals

$18.85 /

-0.16 (-0.84%)

, TNDM

TNDM

/

+

, CERS

Cerus

$4.32 /

-0.055 (-1.26%)

, SBBP

Strongbridge Biopharma

$1.49 /

+0.025 (+1.71%)

, INGN

Inogen

$71.23 /

+1.46 (+2.09%)

, ALDX

Aldeyra

$6.02 /

+0.16 (+2.73%)

, ZGNX

Zogenix

$45.70 /

+0.71 (+1.58%)

, VIVE

Viveve

$3.33 /

+0.31 (+10.26%)

Healthcare Conference…

Healthcare Conference 2019 will be held in New York on November 19-20.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Stifel to hold a conference » 08:49
11/19/19
11/19
08:49
11/19/19
08:49
CBAY

CymaBay

$5.46 /

+0.03 (+0.55%)

, ALXN

Alexion

$107.94 /

-0.38 (-0.35%)

, CBIO

Catalyst Biosciences

$5.28 /

-0.02 (-0.38%)

, QURE

uniQure

$53.11 /

+0.24 (+0.45%)

, GTHX

G1 Therapeutics

$22.40 /

-0.61 (-2.65%)

, HZNP

Horizon Therapeutics

$30.72 /

+0.47 (+1.55%)

, IONS

Ionis Pharmaceuticals

$57.77 /

-0.93 (-1.58%)

, SILK

Silk Road Medical

$37.55 /

-0.14 (-0.37%)

, SAGE

Sage Therapeutics

$145.61 /

-0.75 (-0.51%)

, KIN

Kindred Biosciences

$7.34 /

-0.42 (-5.41%)

, ACOR

Acorda Therapeutics

$1.62 /

-0.195 (-10.77%)

, MASI

Masimo

$149.93 /

+0.15 (+0.10%)

, IRIX

Iridex

$2.03 /

+0.015 (+0.74%)

, BSX

Boston Scientific

$42.29 /

-0.01 (-0.02%)

, PRVL

Prevail Therapeutics

$11.04 /

+0.45 (+4.25%)

, SUPN

Supernus

$22.04 /

-0.06 (-0.27%)

, EVLO

Evelo Biosciences

$6.24 /

+0.025 (+0.40%)

, HRC

Hill-Rom

$104.59 /

-0.4 (-0.38%)

, SVRA

Savara

$0.90 /

+0.1684 (+22.91%)

, AERI

Aerie Pharmaceuticals

$19.01 /

+0.085 (+0.45%)

, TNDM

TNDM

/

+

, CERS

Cerus

$4.38 /

-0.095 (-2.13%)

, SBBP

Strongbridge Biopharma

$1.47 /

-0.105 (-6.69%)

, INGN

Inogen

$69.77 /

-1.53 (-2.15%)

, ALDX

Aldeyra

$5.86 /

-0.18 (-2.98%)

, ZGNX

Zogenix

$44.99 /

-0.12 (-0.27%)

, VIVE

Viveve

$3.02 /

-0.25 (-7.65%)

Healthcare Conference…

Healthcare Conference 2019 will be held in New York on November 19-20.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Cerus upgraded to Buy from Neutral at BTIG » 06:28
11/13/19
11/13
06:28
11/13/19
06:28
CERS

Cerus

$4.29 /

+0.18 (+4.38%)

BTIG analyst Sean Levin…

BTIG analyst Sean Levin assumed coverage on Cerus with a Buy rating, upgrading shares from Neutral, with a $7 price target saying there is no better time to own shares on current weakness. Levin believes a recent FDA guidance document will spur a safer blood supply and strong adoption of CERS' INTERCEPT Platelets. He expects US blood centers to adopt FDA testing of blood for HIV before the March 2021 deadline, which will increase growth rates for Cerus US sales in second half 2020 and beyond.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Cerus backs FY19 product revenue view of $72M-$75M » 16:08
10/30/19
10/30
16:08
10/30/19
16:08
CERS

Cerus

$4.44 /

-0.115 (-2.53%)

The company reaffirms its…

The company reaffirms its 2019 product revenue guidance to the range of $72 million to $75 million. The guidance range represents 18% to 23% growth compared to 2018 reported product revenue and is based on the strong global demand for INTERCEPT platelet kits.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Cerus reports Q3 EPS (13c), consensus (12c) » 16:08
10/30/19
10/30
16:08
10/30/19
16:08
CERS

Cerus

$4.44 /

-0.115 (-2.53%)

Reports Q3 revenue…

Reports Q3 revenue $22.8M, consensus $22.8M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Conference/Events
Baird to hold a conference » 04:55
09/05/19
09/05
04:55
09/05/19
04:55
ACHC

Acadia

$26.11 /

+0.34 (+1.32%)

, ALNA

Allena Pharmaceuticals

$4.12 /

-0.15 (-3.51%)

, APLS

Apellis

$28.50 /

+1.1 (+4.01%)

, ARWR

Arrowhead

$34.25 /

+1.02 (+3.07%)

, BPMC

Blueprint Medicines

$75.35 /

+1.34 (+1.81%)

, CERS

Cerus

$5.03 /

-0.24 (-4.55%)

, EHC

Encompass Health

$60.25 /

-0.58 (-0.95%)

, EIGR

Eiger BioPharmaceuticals

$10.60 /

-0.27 (-2.48%)

, GNCA

Genocea

$3.46 /

+0.24 (+7.45%)

, HARP

Harpoon Therapeutics

$14.50 /

+0.2 (+1.40%)

, HNGR

Hanger

$18.69 /

+0.05 (+0.27%)

, RARE

Ultragenyx

$45.00 /

-6.28 (-12.25%)

, PODD

Insulet

$157.27 /

-10.29 (-6.14%)

, PIRS

Pieris Pharmaceuticals

$4.99 /

+0.15 (+3.10%)

, NVCR

Novocure

$84.39 /

-2.82 (-3.23%)

, NBIX

Neurocrine

$97.70 /

-0.31 (-0.32%)

, MYOV

Myovant Sciences

$8.20 /

+0.07 (+0.86%)

2019 Global Healthcare…

2019 Global Healthcare Conference will be held in New York on September 4-5.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.
友情链接:幸运飞艇官方开奖2020幸运飞艇计划网幸运飞艇走势图幸运飞艇历史开奖结果筛选